Completed PHASE2 INTERVENTIONAL 2-arm NCT03182751

Does Early Administration of Tranexamic Acid Reduce Blood Loss and Perioperative Transfusion Requirement

Does Early Administration of Tranexamic Acid Reduce Blood Loss and Perioperative Transfusion Requirement in Low Energy Hip Fracture Patients?

Sponsor: Mayo Clinic

Conditions Hip Fractures Intertrochanteric Fractures

Interventions Placebo Tranexamic Acid (TXA)

Updated 12 times since 2017 Last updated: Mar 28, 2023 Started: Apr 2, 2018 Primary completion: May 24, 2022 Completion: May 24, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Hip Fractures and Intertrochanteric Fractures and is currently completed. Mayo Clinic leads this study, which shows 12 recorded versions since 2018 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

12 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Apr 2023 — Jul 2024 [monthly]

Completed PHASE2
Dec 2022 — Apr 2023 [monthly]

Completed PHASE2

Status: Recruiting → Completed
Dec 2021 — Dec 2022 [monthly]

Recruiting PHASE2

▶ Show 7 earlier versions

Jan 2021 — Dec 2021 [monthly]

Recruiting PHASE2
Nov 2020 — Jan 2021 [monthly]

Recruiting PHASE2
Nov 2019 — Nov 2020 [monthly]

Recruiting PHASE2
Jun 2019 — Nov 2019 [monthly]

Recruiting PHASE2
Sep 2018 — Jun 2019 [monthly]

Recruiting PHASE2
Jun 2018 — Sep 2018 [monthly]

Recruiting PHASE2
Jun 2017 — Jun 2018 [monthly]

Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Mayo Clinic

Data source: Mayo Clinic

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Rochester, United States